Here, we report safety and efficacy findings from the phase 2/3 part of a global phase 1/2/3 trial evaluating the safety, immunogenicity, and efficacy of 30 μg of BNT162b2 in preventing Covid … A health care worker holds an injection syringe of the phase 3 vaccine trial, developed against the novel coronavirus (COVID-19) pandemic by the U.S. Pfizer … NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the New England Journal of Medicinehas published safety and final efficacy results from the pivotal Phase 3 trial of BNT162b2, their mRNA-based COVID-19 vaccine candidate. Many of these preclinical data and the Phase 1 clinical results contributed to the decision by Pfizer and BioNTech to commence the global (except for China) Phase 2/3 safety and efficacy portion of the clinical study to evaluate potential prevention of COVID-19 disease by BNT162b2. Phase 1/2 study of COVID -19 RNA vaccine BNT162b1 in adults. 3 Two clinical studies assessed the safety, tolerability, and immunogenicity of ascending dose levels of BNT162 modRNA vaccine candidates * Mulligan, M.J. et al.
Intex Challenger K1 Kayak, Best Towns In Pembrokeshire, How Long Does Insecticide Last, What Is A Forwards Main Responsibility In Soccer, Why Is Badminton Considered As A Highly Competitive Sport, Under Armour Women's Golf Shoes, Cheap Old Houses For Sale 2021,